Equities Analysts Issue Forecasts for Surmodics Q3 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for Surmodics in a report issued on Wednesday, February 19th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.08 per share for the quarter, down from their previous forecast of $0.09. The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.18 EPS, Q1 2026 earnings at $0.21 EPS, Q2 2026 earnings at $0.22 EPS and Q3 2026 earnings at $0.17 EPS.

Several other brokerages also recently issued reports on SRDX. StockNews.com initiated coverage on Surmodics in a research report on Monday, February 3rd. They set a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat, Surmodics has an average rating of “Hold” and an average price target of $50.00.

Surmodics Stock Up 0.2 %

NASDAQ:SRDX opened at $34.38 on Friday. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average of $37.12 and a 200-day moving average of $38.42. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44.

Surmodics (NASDAQ:SRDX) last posted its earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Insiders Place Their Bets

In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now directly owns 70,350 shares in the company, valued at $2,774,604. This represents a 9.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SRDX. Modus Advisors LLC bought a new position in shares of Surmodics in the fourth quarter valued at $40,000. Quest Partners LLC increased its holdings in shares of Surmodics by 107,100.0% in the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after buying an additional 1,071 shares in the last quarter. R Squared Ltd bought a new position in shares of Surmodics in the fourth quarter valued at $55,000. Longfellow Investment Management Co. LLC bought a new position in shares of Surmodics in the third quarter valued at $67,000. Finally, Legal & General Group Plc increased its holdings in shares of Surmodics by 34.2% in the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock valued at $137,000 after buying an additional 880 shares in the last quarter. Institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).